Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme.

ABSTRACT:

Aims

To evaluate the efficacy and safety of oral semaglutide versus comparators by patient characteristic subgroups in patients with type 2 diabetes.

Materials and methods

Change from baseline in glycated haemoglobin (HbA1c) and body weight, and achievement of HbA1c <7.0% with oral semaglutide 7 mg, oral semaglutide 14 mg, flexibly dosed oral semaglutide (flex) and comparators were assessed across baseline subgroups (age, race, ethnicity, diabetes duration, body mass index and HbA1c) from the PIONEER programme. Treatment differences were analysed using a mixed model for repeated measurements for continuous variables and a logistic regression model for the binary endpoint. Pooled safety data were analysed descriptively.

Results

Changes from baseline in HbA1c and body w

SUBMITTER: Aroda VR 

PROVIDER: S-EPMC9321749 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature